US Stock Market Move | HUTCHMED (HCM.US) rose nearly 4% after positive results from the SAFFRON III study.

On Monday, HUTCHMED (HCM.US) rose nearly 4%, closing at $12.67. In terms of news, on August 17, HUTCHMED announced that the SAFFRON Phase III study of the combination therapy of gorasiv (savatinib) and osimertinib (Tagrisso) achieved positive top-line results. The study targeted EGFR-mutant non-small cell lung cancer patients who had previously progressed on osimertinib treatment and had tumors with high levels of MET overexpression or amplification. The results showed that the combination therapy had statistically and clinically significant improvements in progression-free survival (PFS) and overall survival (OS) compared to platinum-based doublet chemotherapy.